ArticleOncology letters2023

Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients.

Yi Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.